16 / 51
Immunology 2018
J u l y 0 5 - 0 7 , 2 0 1 8
V i e n n a , A u s t r i a
Page 79
Journal of Clinical Immunology and Allergy
ISSN 2471-304X
1 5
t h
I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology
W
e used four-color ImmunoSpot® assays, in conjunction with
peptide pools that cover the sequence of tyrosinase (Tyr), MAGE-
3, Melan/MART-1, gp100, and NY-ESO-1 to charact erize the melanoma
antigen (MA)-specific CD8 cell repertoire in PBMC of 40 healthy human
donors (HD). Tyr triggered IFN-γ-secreting CD8 cells in 33% HD within
24h of antigen stimulation ex vivo. MAGE-3, Melan/MART-1, and gp100
also induced recall responses in 10%, 5%, and 5% of HD, respectively.
At this time point, these CD8 cells did not yet produce GzB. However,
they engaged in GzB production 72h after antigen stimulation. By
this 72h time point ex vivo, 58% of the HD responded to at least one,
and typically several, of the MA. A closer characterization of the Tyr-
specific CD8 cell repertoire showed it to be of low affinity, and to entail
primarily the stem cell-like subpopulation.
Clonally expanded, stem cell-like melanoma-antigen specific
CD8 memory cells can be detected in healthy humans
Anna Przybyła
1,2
, Ting Zhang
1
, Ruliang Li
1
, Diana R. Roen
1
,
Andrzej Mackiewicz
2
and Paul V Lehmann
1
Cellular Technology Ltd, USA
Poznan University of Medical Sciences, Poland
Biography
Anna Przybyla has completed her PhD from Poznan University of Medical
Science and Postdoctoral fellowship from Cellular Technology Limited
(CTL) in Cleveland, USA. She is an Adjunct in the Department of Cancer
Immunology at the Poznan University of Medical Sciences where she
is also involved in teaching college students. Her research field are
melanoma genetics and immunology, immunomonitoring and genetically
modified melanoma vaccine. She has published 10 papers in medical and
scientific journals.
przybyla.anna.ump@gmail.comAnna Przybyła et al., Insights Allergy Asthma Bronchitis 2018, Volume: 4
DOI: 10.21767/2471-304X-C1-003